In clinical use for some 50 years, the vitamin K antagonist warfarin remains the standard long-term oral anticoagulant. However, warfarin has a number of significant drawbacks driving the search for safer and more effective oral anticoagulants.
-
Venous thromboembolism is the third most common cardiovascular disease after... -
Venous thromboembolism can lead to deep vein thromboses and pulmonary embolisms. -
Patients undergoing major orthopaedic surgery are at an especially high risk... -
In clinical use for some 50 years, the vitamin K antagonist warfarin remains... -
Pradaxa is a new oral anticoagulant under development by Boehringer Ingelheim.
